Share Name Share Symbol Market Type Share ISIN Share Description
Immupharma Plc LSE:IMM London Ordinary Share GB0033711010 ORD 10P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.30 -2.53% 11.575 358,835 16:35:24
Bid Price Offer Price High Price Low Price Open Price
11.45 11.70 11.75 11.35 11.70
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.08 -6.74 -3.99 28
Last Trade Time Trade Type Trade Size Trade Price Currency
16:26:52 AT 141 11.75 GBX

Immupharma (IMM) Latest News

More Immupharma News
Immupharma Takeover Rumours

Immupharma (IMM) Discussions and Chat

Immupharma (IMM) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2020-09-28 15:26:5211.7514116.57AT
2020-09-28 15:19:5611.605,996695.54AT
2020-09-28 15:19:4411.5812,8631,489.99O
2020-09-28 15:15:2511.459,9851,143.28AT
2020-09-28 15:05:4011.4514,0961,613.99AT
View all Immupharma trades in real-time

Immupharma (IMM) Top Chat Posts

Immupharma Daily Update: Immupharma Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker IMM. The last closing price for Immupharma was 11.88p.
Immupharma Plc has a 4 week average price of 10.80p and a 12 week average price of 10.80p.
The 1 year high share price is 32p while the 1 year low share price is currently 6.91p.
There are currently 242,784,071 shares in issue and the average daily traded volume is 959,160 shares. The market capitalisation of Immupharma Plc is £28,102,256.22.
sicilian_kan: Agreed wigwammer. I'm sure the LTHs here will remember that Immunomedics had epratuzumab, which failed its Phase 3 lupus trial in 2015. The Immunomedics share price tanked, collapsing to $2.05. UCB pulled out of the collaboration. Yesterday, just 5 years later, Immunomedics was bought by Gilead for $88 per share, a 44-bagger! I'm not saying that will happen here. What I am saying is exactly what you have quoted wigwammer, namely that there are two relatively near term opportunities that would dwarf the current market cap if successful and which appear to be completely ignored in the current market cap. And we have the Phase 3 trial that Avion will be running for Immupharma too, in lupus. Trial paid for by Avion with Immupharma retaining all European rights plus getting a royalty of up to 17% on US sales, plus milestones. Plus Immupharma is now fully funded through to the end of 2023, as a result of the recent placing, so no dilution. In short, there are a number of irons in the fire and there should also be (never guaranteed of course) opportunities to top slice like last time and to have a free carry. Below again are the products: BioGlucagon - Existing glucagon products; poor solubility, inconvenient - variable dosing creates risks for patients. BioGlucagon has 100% solubility, can be formulated in pre-filled syringe pens and could be used in insulin pumps. Sales of existing products approx. $500m (p.a.). Bio equivalence study, with potential market launch date in 2022. Partnering opportunities. BioAMP-B - offers a potential improvement on Amphotericin-B (“Amp-B”). Amp-B one of the few effective treatments for serious and life threatening fungal infections such as aspergillosis (lung infection). Leading AMP-B, ‘Ambisome’ causes serious kidney toxicity in c.15% of patients. BioAMP-B’s target profile has superior safety profile to Ambisome. Sales of Ambisome in 2019 were $407m (p.a.). Next steps: Bio equivalence study, with potential market launch date in 2022. See hTTps://
marie1980: Nobby, I don’t know whether P3 works or not and I genuinely don’t care. I invest here with a view of 2-3 years. And then get out right before P3 approval with FDA. I don’t know and I don’t care about dosage or any technical things. What I know is in 2 years of time, IMM share price will not be at 20ish. As simple as that.
jaknife: wigwammer, However, that only talks about what happens *IF* the share price is above the Benchmark Price. We are now contemplating what happens *IF* the share price is below the Benchmark Price. "Should the Measured Price be below the Benchmark Price, the Company will receive less than 100 per cent. of the monthly settlement calculated on a pro rata basis and the Company will not be entitled to receive the shortfall at any later date." It expands: "If on the monthly settlement date the calculated Measured Price is below the Benchmark Price by 10 per cent., the settlement on the monthly settlement date will be 90 per cent. of the amount due on that date. Each settlement as so calculated will be in final settlement of Lanstead's obligation on that settlement date." By way of example, let's consider the theoretical circumstance where the share price is exactly zero at the point in time when Lanstead are due to make a payment. How is your comment: "The nature of the contract means that if lanstead repeatedly sell, they will end up with an unhedged and uncapped liability to imm. Highly unlikely they will expose themselves that way :)" correct in that specific circumstance please? JakNife
njb67: Wig 35155 It is good that we agree that there needs to be a significant fund raise, the question is timing and how dilutive it will be for existing shareholders. Btw, I agree that a positive phase 3 result would be a kicker for the share price so any fund raise would be less dilutive than raising money ahead of the trial results, although I do not see the dilution in this scenario as being minimal. The big risk is that IMM run out of cash before then. Given the company announcement that they are looking to start the trial in 2020, we know from previous studies that it will be around six months for them to agree the study design with the FDA, complete site set up and enrol first patient, so we are looking at a mid-2020 start. We also now have an added complexity that we have two companies involved in agreeing the trial design. We do not know who has decision rights if there is a difference of opinion here, if these are jointly held, then the risk is that this slows decision making and progress. Previous 12-month Lupus trials (IMM and AZ) have taken around 3 years to complete (from first patient being enrolled to last data item being captured), there is then a further three-month+ period where analyses take place before the results are reported. So even if everything goes to plan AND Lansdown pay around three times the previously estimated amounts to IMM (based on the average share price being double what it is today for the next 20 months), then the cash will run out at roughly the same time as the earliest point the results are known. IMM cannot allow cash balances to reach zero before acting, they would be trading insolvent if they did not have monies to cover their needs over the rest of the financial year and there is clearly no guarantee that the trial will be positive. For these reasons I suspect they will need to fund raise before the results are known. Worth also remembering that my estimate of 3-4 years is based on an average share price being double what it is today (40p v 20p) for the next 20 months and annual running costs being around £1.8m per annum. If the share price were to average 30p over this time period, then by the same calculation, the money would run out in between two and three years, clearly before the results are known. Equally if costs are higher then the cash runs out earlier. Any fund raise before the results are known will be very dilutive for existing shareholders. Remember that Lanstead paid £2.66m for 19% of IMM when it held the US rights to Lupuzor. How much of what remains of the company would it want today for another £2.66m given that around 40% of the value of Lupuzor has now been given away to Avion? Now clearly by the same reasoning if the share price was to average 50p or 60p over the next 20 months, then these risks are reduced and IMM may not need to raise additional funds until post phase 3 results. So the share price is worth monitoring closely in relation to additional fund raising and further shareholder dilution. Harley 35157 Indeed, very binary. On the morning of the results, the share price will either go up a lot or crash around 90%, which is essentially what it did last time out. This may not be of interest to those looking to trade the share or pump and dump, but it is a consideration for those looking to hold beyond the trial results.
harleydocman: Courtesy of Nolupus on LSE Whilst i can agree with some of what wigwammer says, such as, if the share price stays at 22p for the 20 day trading period prior to the monthly payment date, IMM would be entitled to circa £ 178K from Lanstead...but let's take a look back first Lanstead payments are at the beginning of each month, so the payments were to be calculated on the 'mesured price' of the share price , for august, sept, oct, nov....still following ? Let's read the RNS again :-) If the measured share price (the "Measured Price"), calculated as the average volume weighted share price of the Company's Ordinary Shares over a period of 20 trading days prior to the monthly settlement date, exceeds the Benchmark Price, the Company will receive more than 100 per cent. of that monthly settlement due on a pro rata basis according to the excess of the Measured Price over the Benchmark Price. There is no upper limit placed on the additional proceeds receivable by the Company as part of the monthly settlements and the amount available in subsequent months is not affected. Should the Measured Price be below the Benchmark Price, the Company will receive less than 100 per cent. of the monthly settlement calculated on a pro rata basis and the Company will not be entitled to receive the shortfall at any later date. For illustration purposes, i am going to take an average of 10p for "the mesured price " for august, sept, oct, even november , because the share price did'nt peak till the 28th.. so the monthly payments from Lanstead were circa £74K instead of £ 111k which is the benchmark payment . Therefore Lanstead have according to my estimate paid a total of £296K to IMM in 2019 instead of £444K ( benchmark payment ) (loss of circa £148K ) So let's hope the share price stays at 22p / or above for the next 20 months
ny boy: n.b. Under the Lanstead deal, IMM will receive monthly payments from Lanstead for the shares that they have issued them. If the share price averages over the 34.667p benchmark price, IMM will make more than the £4.43m estimated. If the share price is at double that for the month, IMM receive double that month. Conversely, if the share is at half the benchmark price for the month, IMM receive half that month. Note this is not an equity line of credit. Lanstead have all the shares. There is no fresh dilution each month and Lanstead do not sell every month. Indeed they held back in selling IMM until they could place with new IIs wanting to buy in,
whatsthepoint: From LSE 2019-12-06 15:16:00Investment bank Life Sciences Division upgraded its share price target to 100p from 76p on the back of the recent deal with US speciality drugs group Avion PharmaceuticalsImmuPharma PLC - ImmuPharma s Lupuzor could be US blockbuster, says Life Sciences DivisionImmuPharma PLC's (LON:IMM) lupus candidate Lupuzor could become a US blockbuster by generating over US$1bn revenues per year, according to Life Sciences Division.The investment bank raised its target for the AIM-listed drug developer's share price to 100p from 76p on the back of the recent deal with US speciality drugs group Avion Pharmaceuticals.READ: ImmuPharma shoots up 300% after it inks US licensing deal for flagship drug LupuzorAvion will fund a new phase III trial, while Immupharma will also receive milestone payments and an agreed 17% royalty on sales.ImmuPharma has the potential to rack in annual royalties of up to US$170mln from the deal, according to the Life Sciences Division analysts.This deal is only exclusive to the US market, meaning ImmuPharma can look for other distribution partners in other geographies, such as Europe, where there is no need for a new trial given Avion's funding commitment.Further agreements will allow ImmuPharma to multiply income from Lupuzor with other royalties and milestone payments.According to Life Sciences Division, Lupuzor may get second or third place in the US market if rival AstraZeneca PLC's (LON:AZN) Anifrolumab gets a US licensing deal."Lupuzor with a 71.1% response rate in the anti-ds DNA auto antibody-positive patients, could also eventually be the product with the best overall response rate and safety profile in the market," LSD analysts added.Shares in ImmuPharma were trading 3% higher on Friday afternoon at the 21.6p.
spawny100: Never mind last couple of years petroc - IMM share price is back to 2003 levels. Anyone who sees value at these prices needs to seriously analyse why imo.
growthinvestor2001: spmc - I remember you making wild claims about IMM share price too - look how that worked out. Just keep it to yourself....try and stop ramping / pumping for just one minute yeah?
hamhamham1: Merlion. Look, research companies are money pits they dilute shares and raise money all day long. They suck up money and nearly always end up with nothing of value to show for it. IMM share price went up based upon an immenant good p3 readout and thus real saleable asset value. It failed by over x5 the target level p value. The 22p is based upon that and not some pi investor hopes.
Immupharma share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200929 04:08:46